Shijiazhuang Yiling pharmacy

Hebei Yiling Pharmaceutical Group, a national key high-tech enterprise, is located in Shijiazhuang National High-tech Industrial Development Zone, with Beijing-Shijiazhuang Expressway in the north and Tianshan Street in the east. Its headquarters covers an area of more than 16 mu. The buildings are magnificent, the environment is fresh and elegant, the GMP modern Chinese medicine production base is advanced, and the GLP R&D center is full of talents and first-class in China. The group company was founded in 1992 by Dr. Wu Yiling, a doctoral supervisor. Under his leadership, the group company has always adhered to the integration of scientific research, clinical practice, production and marketing with science and technology as the guide and < P > market as the leader, and applied modern high and new technology to study traditional Chinese medicines and biological medicines for treating difficult diseases. During the development of the group company, it has accumulated a profound corporate culture and gathered a large number of innovative and dedicated high-tech talents such as doctors and masters in medicine. Post-Doctoral Research Center, the Ministry of Personnel, has made remarkable achievements in the research, development and production of modern Chinese medicine and biopharmaceuticals with its high-quality talent team and high-tech and equipment platform. Relying on its own institutional advantages, the company has realized industrialization and internationalization, and has developed into a modern pharmaceutical group with great influence in China and five branches. Entering the new century, Yiling people will continue to carry forward the enterprise spirit of "unity, forge ahead, honesty and dedication", take the revitalization of national medicine as their responsibility, strive to build the brand of Chinese medicine, follow the frontier of medical science and technology, build international leading products, build a platform for science and technology and market, sincerely cooperate with friends from all walks of life, and strive to achieve the grand goal of "devoting to science and technology and a healthy tomorrow". Yiling Pharmaceutical Co., Ltd., located in Shijiazhuang High-tech Development Zone, Hebei Province, was founded in 1992 by Professor Wu Yiling, academician of China Academy of Engineering, chief scientist of National 973 Project and doctoral supervisor. After more than ten years of development, it has become a modern medicine high-tech industrial group with six branches, including Yiling Pharmaceutical Research Institute, Shijiazhuang Yiling Pharmaceutical Co., Ltd., Hebei Yiling Hospital, Anguo Yiling Chinese Herbal Pieces Co., Ltd., Beijing Yiling Pharmaceutical Co., Ltd. and Beijing Yiling Biological Co., Ltd., which integrates scientific research, teaching, clinic, production and marketing. It is one of the top 1 pharmaceutical companies in China and the top 1 independent innovation ability of Chinese patent medicine manufacturing industry in China. It has won hundreds of honorary titles, such as national key high-tech enterprises, leading enterprises in pharmaceutical manufacturing industry, social responsibility contribution award of pharmaceutical enterprises, honest enterprises in Hebei Province and enterprises with the most social responsibility in Hebei Province. Yiling Pharmaceutical insists on taking science and technology as the guide, taking the market as the leader, promoting the industrialization of traditional Chinese medicine with academic innovation of traditional Chinese medicine, and using modern high technology to research and develop traditional Chinese medicine, western medicine and biological medicine. Relying on Yiling Medical Research Institute, it has been recognized by the state as the National Enterprise Technology Center, Post-Doctoral Research Center, the National 863 Achievement Transformation Base, the first batch of international scientific and technological cooperation bases, Hebei New Chinese Medicine R&D and Achievement Industrialization Center, and Shijiazhuang Compound Chinese Medicine Engineering R&D Center. He has successively undertaken more than 3 national, provincial and ministerial-level projects such as National 973, National 863, National Tenth Five-Year Plan and National Natural Science Foundation, won more than 1 invention patents at home and abroad, and won more than 2 national, provincial and ministerial-level scientific and technological awards such as the second prize of national scientific and technological progress and the second prize of national technological invention. A series of national new drugs with independent intellectual property rights have been developed and rapidly industrialized, and a new way to accelerate the development of traditional Chinese medicine through academic innovation has been found. Yiling Pharmaceutical has formed a product group dominated by Tongxinluo Capsule, Shensong Yangxin Capsule and Lianhua Qingwen Capsule, and has listed 9 patented new drugs and more than 1 kinds of imitation and generic drugs. Subsequent research and development will make the product series more perfect. Tongxinluo Capsule is the only Chinese patent medicine for treating cardiovascular and cerebrovascular diseases that won three national awards in China. It has become the leading brand of Chinese patent medicine for treating cardiovascular and cerebrovascular diseases and ranks among the top three in the domestic market. Lianhua Qingwen Capsule is a high-tech demonstration project of the National Development and Reform Commission and a national OTC Class A variety, which has played an important role in fighting SARS, avian influenza and the current global outbreak of influenza A.. A lot of scientific research by a group of authoritative scientific research machines in China has proved that it can be broad-spectrum antiviral, effectively bacteriostatic, antipyretic and anti-inflammatory, effectively improve symptoms such as fever, sore throat and cough, enhance immunity, and improve the body's ability to resist diseases. The anti-H1N1 influenza virus is better than Tamiflu. Shensong Yangxin Capsule is the only Chinese patent medicine to carry out clinical research on antiarrhythmia in evidence-based medicine in China. Its clinical efficacy and safety have been unanimously recognized by medical experts and consumers, which has played a positive demonstration role in the modernization and internationalization of clinical research of traditional Chinese medicine in China. Yiling Medical Research Institute is the leader of the development of the group company. It has built a modern high-tech R&D platform conforming to GLP standards, with more than 1 scientific researchers, 18 doctors and postdoctoral fellows, 27 masters and 35 people with the title of subtropical high or above. It has cooperated with academicians and experts from well-known universities and research institutes at home and abroad to carry out R&D projects, and its strong talent team has provided strong technical support for the research and development of new drugs. Over the past decade, it has developed 8 national new drugs with independent intellectual property rights. Yiling Institute of Medicine has set up a pharmacy department, a pharmacology department, a clinical department and a registered patent department. It is equipped with world-advanced analytical instruments such as high performance liquid chromatography, gas chromatography, thin-layer scanning, atomic absorption, nuclear magnetic resonance, infrared spectroscopy and gas chromatography-mass spectrometry, as well as advanced process research equipment such as supercritical extraction, adsorption separation, membrane separation and nano-preparation, and a complete pilot plant. The research system of extraction, separation and purification of effective components or effective parts of modern Chinese medicine and the quality control system of Chinese medicine fingerprint have been established. Yiling Institute of Medicine has the research and development capabilities of Chinese medicine compound, Chinese medicine monomer, Chinese medicine components compatible with various new drugs and western medicine imitation wound medicine, and has become a drug research and development institution with certain influence in China. Shijiazhuang Yiling Pharmaceutical Co., Ltd. has a production line of capsules, soft capsules, tablets, granules, injections and dripping pills that have passed GMP and ISO91 quality system certification, and a chemical workshop that meets the EU certification standards and is guided by foreign expert groups, with an annual output value of 5 billion yuan. Yiling Pharmaceutical Co., Ltd. introduced advanced equipment and technology in all aspects of large-scale production of traditional Chinese medicine, and adopted advanced technologies such as dynamic extraction, external circulation concentration, supercritical CO2 extraction, high-speed centrifugal spray drying and one-step granulation to improve the quality of modern Chinese medicine. The national high-tech development plan project-Tongxinluo capsule superfine powder process upgrading project undertaken by Tsinghua University * * * has successfully applied superfine powder technology to the production of Chinese patent medicine for the first time, which has become a national standard and won a national prize. Modern production line, reliable product quality and strong production capacity ensure that scientific research results can be quickly transformed into high-quality new products and put on the market. Yiling Chinese Herbal Pieces Co., Ltd. is the raw material base of Yiling Pharmaceutical Group. The company is located in Anguo, the drug capital, with an area of 2m2 and a building area of 1m2. It is a modern enterprise integrating standardized cultivation of medicinal materials, processing and trade of traditional Chinese herbal pieces and refined Chinese herbal pieces. In 24, it was the first to pass the GMP certification of Chinese herbal pieces by the State Food and Drug Administration. In order to ensure the quality of raw materials, the company has established planting and breeding bases meeting GAP requirements in Anguo, Jilin, Gucheng and other places, and established QA and QC quality assurance systems. At the same time, the decoction pieces company has carried out the processing and sales business of traditional Chinese medicine decoction pieces, and established good business relations with thousands of hospitals and pharmaceutical companies.